首页> 美国卫生研究院文献>Orphanet Journal of Rare Diseases >Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule
【2h】

Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule

机译:缺乏基于BDNF和TTC融合分子的非病毒ALS基因疗法的协同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundAmyotrophic lateral sclerosis (ALS) is one of the most devastating neurodegenerative diseases. Neurotrophic factors have been widely tested to counteract neurodegenerative conditions, despite their unspecific neuronal access. The non-toxic C-terminal fragment of the tetanus toxin (TTC) heavy chain has been studied not only as a carrier molecule to the CNS but also as a neuroprotective agent. Because the neurotrophic effects of BDNF have been demonstrated in vitro and in vivo, the question addressed in this work is whether a fusion molecule of BDNF-TTC may have a synergistic effect and enhance the neuroprotective properties of TTC alone in a mouse model of ALS.
机译:背景肌萎缩性侧索硬化症(ALS)是最具破坏性的神经退行性疾病之一。尽管神经营养因子具有非特异性的神经通路,但它们已被广泛测试以抵消神经变性疾病。破伤风毒素(TTC)重链的无毒C末端片段已被研究,不仅作为CNS的载体分子,而且作为神经保护剂。因为已经在体外和体内证明了BDNF的神经营养作用,所以这项工作解决的问题是,在ALS小鼠模型中,BDNF-TTC的融合分子是否可能具有协同作用并增强TTC的神经保护特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号